Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>With pathway‐specific trials in PD associated with variants in the glucocerebrosidase gene (PD<sub>GBA</sub>) under way, we need markers that confirm the impact of genetic variants in patient‐derived biofluids in order to allow patient stratification merely based on genetics and that might serve as biochemical read‐out for target engagement. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To explore GBA‐pathway‐specific biomarker profiles cross‐sectionally (TUEPAC‐MIGAP, PPMI) and longitudinally (PPMI).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>We measured enzyme activity of the lysosomal glucocerebrosidase, CSF levels of glucosylceramides (upstream substrate of glucocerebrosidase), CSF levels of ceramides (downstream product of glucocerebrosidase), lactosylceramides, sphingosines, sphingomyelin (by‐products) and CSF levels of total α‐synuclein in PD<sub>GBA</sub> patients compared to PD<sub>GBA_wildtype</sub> patients. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Cross‐sectionally in both cohorts and longitudinally in PPMI: (1) glucocerebrosidase activity was significantly lower in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. (2) CSF levels of upstream substrates (glucosylceramides species) were higher in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. (3) CSF levels of total α‐synuclein were lower in PD<sub>GBA</sub> compared to PD<sub>GBA_wildtype</sub>. All of these findings were most pronounced in PD<sub>GBA</sub> with severe mutations (PD<sub>GBA_severe</sub>). Cross‐sectionally in TUEPAC‐MIGAP and longitudinally in PPMI, CSF levels of downstream‐products (ceramides) were higher in PD<sub>GBA_severe</sub>. Cross‐sectionally in TUEPAC‐MIGAP by‐products sphinganine and sphingosine‐1‐phosphate and longitudinally in PPMI species of by‐products lactosylceramides and sphingomyelin were higher in PD<sub>GBA_severe</sub>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Interpretation</h3><p>These findings confirm that GBA mutations have a relevant functional impact on biomarker profiles in patients. Bridging the gap between genetics and biochemical profiles now allows patient stratification for clinical trials merely based on mutation status. Importantly, all findings were most prominent in PD<sub>GBA</sub> with severe variants. © 2021 International Parkinson and Movement Disorder Society </p></section>

Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI

Elevation of gangliosides in four brain regions from Parkinson’s disease patients with a GBA mutation

The Mutation Matters: CSF Profiles of GCase , Sphingolipids, α‐Synuclein in PD GBA

Lipidomic Profiling Reveals Shared and Distinct Pathological Signatures in Sporadic Parkinson's Disease and GBA Mutation Carriers: Implications for Disease Mechanisms

Plasma glucosylceramide levels are regulated by ATP10D and are not involved in Parkinson's disease pathogenesis.

Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease

Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson's Disease

Comparing GBA1-Parkinson's disease and idiopathic Parkinson's disease: α-Synuclein oligomers and synaptic density as biomarkers in the skin biopsy

Neuronal Accumulation Of Glucosylceramide In A Mouse Model Of Neuronopathic Gaucher Disease Leads To Neurodegeneration

Characterization of a pathogenic variant in GBA for Parkinson’s disease with mild cognitive impairment patients

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutation

Effects of GBA1 Variants and Prenatal Exposition on the Glucosylsphingosine (Lyso-Gb1) Levels in Gaucher Disease Carriers

Glucocerebrosidase Mutations Influence the Natural History of Parkinson's Disease in a Community-Based Incident Cohort.

Genome-wide association study of glucocerebrosidase activity modifiers

Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers

Neurosteroid Levels in GBA Mutated and Non-Mutated Parkinson's Disease: A Possible Factor Influencing Clinical Phenotype?

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson's Disease: Pathogenesis and Therapeutic Implications

The Molecular Impact of Glucosylceramidase Beta 1 (Gba1) in Parkinson's Disease: a New Genetic State of the Art

Peripheral Upregulation of Parkinson's Disease-Associated Genes Encoding α-Synuclein, β-Glucocerebrosidase, and Ceramide Glucosyltransferase in Major Depression

Follow-up of pre-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF